VIM and hepatocellular carcinoma: Moreover, in the HepG2.2.15 cells, HBV‐genome transfected HepG2 cells, and DOX‐treated HepG2‐Tet‐ON‐HBx cells treated with pTT5‐anti‐HBx plasmids, we found that intracellular product of anti‐HBx mAb significantly suppressed the HBx‐expression level in HBV‐related HCC cells, while followed by the inhibition of p‐AKTThr308/Ser473, as well as the downregulation of MMP2, MMP9, and vimentin expression, and the increased levels of E‐cadherin (Figure 8D–F).